Research Article
Immune Score Predicts Outcomes of Gastric Cancer Patients Treated with Adjuvant Chemoradiotherapy
Table 1
Correlation between IS and clinical parameters.
| Variables | Immunoscore | value | Low | Median | High | n = 20 | n = 57 | n = 24 | (19.8%) | (56.4%) | (23.8%) |
| Sex | | | | | Male | 15(21.4%) | 39(55.7%) | 16(22.9%) | 0.876 | Female | 5(16.1%) | 18(58.1%) | 8(25.8%) | |
| Age | | | | 0.311 | <65 | 11(17.7%) | 33(53.2%) | 18(29.0%) | | ≥65 | 9(23.1%) | 24(61.5%) | 6(15.4%) | |
| ECOG | | | | 0.433 | 0 | 13(21.0%) | 32(51.6%) | 17(27.4%) | | 1 | 7(17.9%) | 25(64.1%) | 7(17.9%) | |
| LDH (U/L) | | | | 0.999 | <250 | 18(20.2%) | 50(56.2%) | 21(23.6%) | | ≥250 | 2(22.2%) | 5(55.6%) | 2(22.2%) | | Unknown | 0(0.0%) | 2(66.7%) | 1(33.3%) | |
| CEA (ng/ml) | | | | 0.492 | <5 | 16(19.3%) | 45(54.2%) | 22(26.5%) | | ≥5 | 1(14.3%) | 6(85.7%) | 0(0.0%) | | Unknown | 3(30.0%) | 5(50.0%) | 2(20.0%) | |
| Tumor location | | | | 0.248 | Upper 1/3 | 5(23.8%) | 9(42.9%) | 7(33.3%) | | Middle 1/3 | 4(26.7%) | 10(66.7%) | 1(6.7%) | | Lower 1/3 | 9(15.5%) | 33(56.9%) | 16(27.6%) | | Total stomach | 2(28.6%) | 5(71.4%) | 0(0.0%) | |
| Tumor size (cm) | | | | 0.029 | <5 | 7(12.3%) | 32(56.1%) | 18(31.6%) | | ≥5 | 13(29.5%) | 25(56.8%) | 6(13.6%) | |
| Surgery type | | | | 0.010 | Subtotal gastrectomy | 8(12.1%) | 38(56.7%) | 20(30.3%) | | Total gastrectomy | 12(34.3%) | 19(54.3%) | 4(11.4%) | |
| Differentiation grade | | | | 0.092 | Moderate | 3(8.8%) | 20(58.8%) | 11(32.4%) | | Poor | 17(25.4%) | 37(55.2%) | 13(19.4%) | |
| Borrmann classification | | | | 0.339 | I | 0(0%) | 2(66.7%) | 1(33.3%) | | II | 3(15.8%) | 9(47.4%) | 7(36.8%) | | III | 14(21.2%) | 36(54.5%) | 16(24.2%) | | IV | 3(23.1%) | 10(76.9%) | 0(0%) | |
| pT | | | | 0.006 | 1 | 0(0.0%) | 1(16.7%) | 5(83.3%) | | 2 | 0(0.0%) | 6(66.7%) | 3(33.3%) | | 3 | 4(11.8%) | 23(67.6%) | 7(20.6%) | | 4 | 16(30.8%) | 27(51.9%) | 9(17.3%) | |
| pN | | | | 0.023 | 0 | 0(0.0%) | 5(71.4%) | 2(28.6%) | | 1 | 0(0.0%) | 10(90.9%) | 1(9.1%) | | 2 | 4(15.4%) | 11(42.3%) | 11(42.3%) | | 3 | 16(28.1%) | 13(54.4%) | 10(17.5%) | |
| pTNM | | | | 0.009 | Stage II | 0(0.0%) | 14(63.6%) | 8(36.4%) | | Stage III | 20(25.3%) | 43(54.4%) | 16(20.3%) | |
| LVI | | | | 0.020 | Negative | 2(5.4%) | 24(64.9%) | 11(29.8%) | | Positive | 18(28.1%) | 33(51.6%) | 13(20.3%) | |
| PNI | | | | 0.673 | Negative | 6(15.4%) | 23(59.0%) | 10(25.6%) | | Positive | 14(22.6%) | 34(54.8%) | 14(22.6%) | |
|
|
Values in bold with < 0.05. LVI, lymphatic and vascular invasion; PNI, perineural invasion. |